NYSE ARCA | ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index.
The index seeks to track the performance of the common stock ofU. S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| CELC | Celcuity LLC | Healthcare | Biotechnology | 3.13% |
| ALPN | Alpine Immune Sciences Inc | Healthcare | Biotechnology | 2.68% |
| LBPH | Longboard Pharmaceuticals Inc | Healthcare | Biotechnology | 2.54% |
| NVAX | Novavax Inc | Healthcare | Biotechnology | 2.12% |
| GERN | Geron Corporation | Healthcare | Biotechnology | 1.84% |
| 6XC | SOLENO THERAPEUT. DL-001 | Healthcare | Biotechnology | 1.76% |
| MORF | Morphic Holding Inc | Healthcare | Biotechnology | 1.74% |
| VERV | Verve Therapeutics Inc | Healthcare | Biotechnology | 1.36% |
| LQDA | Liquidia Technologies Inc | Healthcare | Biotechnology | 1.36% |
| TERN | Terns Pharmaceuticals Inc | Healthcare | Biotechnology | 1.36% |
| XERS | Xeris Pharmaceuticals Inc | Healthcare | Biotechnology | 1.32% |
| KRYS | Krystal Biotech Inc | Healthcare | Biotechnology | 1.28% |
| UMRX | Cogent Biosciences Inc | Healthcare | Biotechnology | 1.25% |
| UPB | Upstream Bio, Inc. | Healthcare | Biotechnology | 1.24% |
| PRTA | Prothena Corporation plc | Healthcare | Biotechnology | 1.24% |
| NK | NantKwest Inc | Healthcare | Biotechnology | 1.23% |
| ARCT | Arcturus Therapeutics Holdings Inc | Healthcare | Biotechnology | 1.17% |
| STOK | Stoke Therapeutics Inc | Healthcare | Biotechnology | 1.17% |
| NUVB | Nuvation Bio Inc | Healthcare | Biotechnology | 1.15% |
| CNTA | Centessa Pharmaceuticals PLC ADR | Healthcare | Biotechnology | 1.14% |